Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: A randomized double-blind placebo-controlled crossover study

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 587-594

  Rennings, A J ^a   Russel, F G ^a   Li, Y ^a   Deen, P M ^a   Masereeuw, R ^a   Tack, C J ^a   Smits, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; AMILORIDE; ATRIAL NATRIURETIC FACTOR; CREATININE; DIURETIC AGENT; EPITHELIAL SODIUM CHANNEL; FUROSEMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; RENIN; ROSIGLITAZONE; SODIUM;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANKLE EDEMA; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG RESPONSE; DRUG URINE LEVEL; EXOSOME; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOADING DRUG DOSE; MALE; NATRIURESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; UPREGULATION;

ADULT; AMILORIDE; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EPITHELIAL SODIUM CHANNEL; EXOSOMES; FEMALE; FUROSEMIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KIDNEY; MALE; MIDDLE AGED; NATRIURESIS; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 79952984721     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.360     Document Type: Article

References (46)

1. Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
2. Kahn, S.E. et al. Glycemic durability of rosiglitazone, Metformin, Or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006). (Pubitemid 44903747)
3. Parulkar, A.A., Pendergrass, M.L., Granda-ayala, R., Lee, T.R. & Fonseca, V.A. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134, 61-71 (2001). (Pubitemid 32037344)
4. Rennings, A.J. et al. Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome. Eur. Heart J. 31, 983 (2010).
5. Nissen, S.E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
6. Home, P.D. et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, Randomised, Open-label trial. Lancet 373, 2125-2135 (2009).
7. Gerstein, H.C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
8. Graham, D.J. et al. Risk of acute myocardial infarction, Stroke, Heart failure, And death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
9. Werner, A.L. & Travaglini, M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21, 1082-1099 (2001). (Pubitemid 32807869)
10. Dormandy, J.A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the pROactive Study (pROspective pioglitazone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005). (Pubitemid 41416583)
11. Guan, Y. et al. Thiazolidinediones expand body fluid volume through ppaRγ stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11, 861-866 (2005). (Pubitemid 41161118)
12. Hong, G. et al. PpaRγ activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 17, 1966-1968 (2003).
13. Loffing, J. & Korbmacher, C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch. 458, 111-135 (2009).
14. Rossier, B.C., Canessa, C.M., Schild, L. & Horisberger, J.D. Epithelial sodium channels. Curr. Opin. Nephrol. Hypertens. 3, 487-496 (1994). (Pubitemid 2138428)
15. Karalliedde, J., Buckingham, R., Starkie, M., Lorand, D., Stewart, M. & Viberti, G.; Rosiglitazone Fluid Retention Study Group. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J. Am. Soc. Nephrol. 17, 3482-3490 (2006). (Pubitemid 44865290)
16. Pérez-ayuso, R.M. et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the reninaldosterone system. Gastroenterology 84, 961-968 (1983).
17. Semenkovich, C.F. TZDs and diabetes: testing the waters. Nat. Med. 11, 822-824 (2005). (Pubitemid 41161107)
18. Jeunemaitre, X. et al. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J. Hypertens. 15, 1091-1100 (1997). (Pubitemid 27420390)
19. Hirsch, I.B., Kelly, J. & Cooper, S. Pulmonary edema associated with troglitazone therapy. Arch. Intern. Med. 159, 1811 (1999). (Pubitemid 29379147)
20. Thomas, M.L. & Lloyd, S.J. Pulmonary edema associated with rosiglitazone and troglitazone. Ann. Pharmacother. 35, 123-124 (2001). (Pubitemid 32216290)
21. Niemeyer, N.V. & Janney, L.M. Thiazolidinedione-induced edema. Pharmacotherapy 22, 924-929 (2002). (Pubitemid 34743442)
22. Odlind, B. & Beermann, B. Renal tubular secretion and effects of furosemide. Clin. Pharmacol. Ther. 27, 784-790 (1980). (Pubitemid 10072965)
23. Brater, D.C. Diuretic therapy. N. Engl. J. Med. 339, 387-395 (1998). (Pubitemid 28363803)
24. Van Meyel, J.J., Smits, P., Russel, F.G., Gerlag, P.G., Tan, Y. & Gribnau, F.W. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin. Pharmacol. Ther. 51, 440-444 (1992).
25. Beermann, B. Kinetics and dynamics of furosemide and slow-acting furosemide. Clin. Pharmacol. Ther. 32, 584-591 (1982). (Pubitemid 13096701)
26. Rennings, A.J., Smits, P., Stewart, M.W. & Tack, C.J. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulintreated patients with type 2 diabetes: a randomised, Controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 53, 1856-1866 (2010).
27. Nesto, R.W. et al.; american Heart association; american Diabetes association. Thiazolidinedione use, Fluid retention, And congestive heart failure: a consensus statement from the american Heart association and american Diabetes association. October 7, 2003. Circulation 108, 2941-2948 (2003). (Pubitemid 37517824)
28. Chen, L. et al. Gi262570, A peroxisome proliferator-activated receptor {gamma} agonist, Changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 312, 718-725 (2005). (Pubitemid 40189571)
29. Vallon, V. et al. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J. Am. Soc. Nephrol. 20, 721-729 (2009).
30. Nofziger, C. & Blazer-Yost, B.L. PpaRγ agonists, Modulation of ion transporters, And fluid retention. J. Am. Soc. Nephrol. 20, 2481-2483 (2009).
31. Esteva-Font, C. et al. Are Sodium Transporters in Urinary Exosomes Reliable Markers of Tubular Sodium Reabsorption in Hypertensive patients? Nephron. Physiol. 114, 25-34 (2010).
32. Gonzales, P., Pisitkun, T. & Knepper, M.A. Urinary exosomes: is there a future? Nephrol. Dial. Transplant. 23, 1799-1801 (2008). (Pubitemid 351768175)
33. Wetzels, J.F., Wiltink, P.G., Hoitsma, A.J., Huysmans, F.T. & Koene, R.A. Diuretic and natriuretic effects of nifedipine in healthy persons. Br. J. Clin. Pharmacol. 25, 547-553 (1988).
34. Van der Heijden, A.G., Huysmans, F.T. & Van Hamersvelt, H.W. Foot volume increase on nifedipine is not prevented by pretreatment with diuretics. J. Hypertens. 22, 425-430 (2004). (Pubitemid 38251004)
35. Rennings, A.J., Smits, P., Stewart, M.W. & Tack, C.J. Fluid retention and vascular effects of rosiglitazone in obese, Insulin-resistant, Nondiabetic subjects. Diabetes Care 29, 581-587 (2006). (Pubitemid 44115358)
36. Grundy, S.M. et al.; american Heart association; National Heart, Lung, And Blood institute. Diagnosis and management of the metabolic syndrome: an american Heart association/National Heart, Lung, And Blood institute Scientific Statement. Circulation 112, 2735-2752 (2005). (Pubitemid 41532612)
37. Jones, K.M. et al. Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. Pharmacotherapy 17, 263-270 (1997). (Pubitemid 27133351)
38. Weiss, P., Hersey, R.M., Dujovne, C.A. & Bianchine, J.R. The meetabolism of amiloride hydroloride in man. Clin. Pharmacol. Ther. 10, 401-406 (1969).
39. Pickkers, P., Van Beek, M., Hughes, A.D., Russel, F.G., Thien, T. & Smits, P. Presence and mechanism of direct vascular effects of amiloride in humans. J. Cardiovasc. Pharmacol. 34, 388-393 (1999). (Pubitemid 29393645)
40. Kamsteeg, E.J., Wormhoudt, T.A., Rijss, J.P., Van Os, C.H. & Deen, P.M. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J. 18, 2394-2400 (1999). (Pubitemid 29213273)
41. Pisitkun, T., Shen, R.F. & Knepper, M.A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 101, 13368-13373 (2004). (Pubitemid 39209672)
42. Russel, F.G., Tan, Y., Van Meijel, J.J., Gribnau, F.W. & Van Ginneken, C.A. Solidphase extraction of furosemide from plasma and urine and subsequent analysis by high-performance liquid chromatography. J. Chromatogr. 496, 234-241 (1989).
43. Forrest, G., Mcinnes, G.T., Fairhead, A.P., Thompson, G.G. & Brodie, M.J. Simple high-performance liquid chromatographic method for the measurement of amiloride in body fluids. J. Chromatogr. 428, 123-130 (1988).
44. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985). (Pubitemid 15018832)
45. Lukaski, H.C. Methods for the assessment of human body composition: traditional and new. Am. J. Clin. Nutr. 46, 537-556 (1987). (Pubitemid 18005716)
46. Van Hamersvelt, H.W., Kloke, H.J., De Jong, D.J., Koene, R.A. & Huysmans, F.T. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J. Hypertens. 14, 1041-1045 (1996). (Pubitemid 26306071)